Literature DB >> 8378029

A new device for the treatment of pleural malignancies: intrapleural chemohyperthermia preliminary report.

P Y Carry1, A Brachet, F N Gilly, A C Sayag, P Y Petit, C Rochette, P Mulsant, B Guibert, G Braillon, V Banssillon.   

Abstract

The prognosis of malignant pleural tumors remains extremely unfavorable. The aim of this study is to evaluate the combination of intrathoracic intrapleural chemotherapy and intrapleural hyperthermia (ITCH) in these diseases. Under anesthesia, 5 men were studied. After pleurectomy for mesothelioma (3/5) or adenocarcinoma (2/5), ITCH is carried out for over 60 min, either with mitomycin C (4/5) or cisplatin (1/5). No pre- or postoperative death occurred. The maximal pleural temperature is 42.6 degrees C. The blood level of mitomycin C never reached the systemic toxic level. All the patients were discharged from the surgical ward, 3 are still alive 15 months later. Therefore, ITCH appears to be a safe and reliable therapy.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378029     DOI: 10.1159/000227208

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  3 in total

Review 1.  Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches.

Authors:  J W Upham; M J Garlepp; A W Musk; B W Robinson
Journal:  Thorax       Date:  1995-08       Impact factor: 9.139

Review 2.  Hyperthermic intrathoracic chemotherapy for the treatment of malignant pleural effusion caused by breast and ovarian cancer: A systematic literature review and pooled analysis.

Authors:  Ioannis Karampinis; Anna Dionysopoulou; Christian Galata; Katrin Almstedt; Maurizio Grilli; Annette Hasenburg; Eric D Roessner
Journal:  Thorac Cancer       Date:  2022-02-22       Impact factor: 3.500

3.  Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies.

Authors:  O Monneuse; A C Beaujard; B Guibert; F N Gilly; P Mulsant; P Y Carry; M Benoit; O Glehen
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.